arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

EDAP TMS SA

FOCL
$4.69 ▲ +0.37 (+8.56%) at close
Healthcare ·Electromedical & Electrotherapeutic Apparatus ·USElectromedical & Electrotherapeutic Apparatus
17 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
14
Health
Poor
Bearish
auto_awesome

Analytical Summary

EDAP TMS SA faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $176.0M
Dividend Yield
Revenue Growth 38.8%
Op. Margin -60.8%
ROIC -23.1%
FCF / Share $-0.10
Trailing P/E
Price / Book
FCF Yield
Debt / Equity -12.37
info Valuation on last close. End-of-day price, Sep 23, 2026.

17-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$13.20M
↑ +38.8%
Net Income Profit after all expenses
$-14.49M
↓ -126.1%
Operating Margin Operating profit as % of sales
-60.8%
↓ -47.1% 7th
FCF / Share Free cash flow per share
$-0.10
↑ +21.8%
Long-Term Debt Long-term obligations
$38.05M
↑ +99.6%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
7
Returns
5
Financial Health
21
Cash Quality
42

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 15 years · 17 quarters